BioSpace News Archive

Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced it has received special authorization from Health Canada to initiate a research program

Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced that it has received the Conformité Européene (CE) Mark approval for the Initial Serological Disease Screening (SDS) Microarray.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), today announced that the Company will release fourth quarter and full year 2019 financial results on Monday, February 24, 2020 after the close of market.

Verona Pharma plc announces publication of Phase 2b clinical trial results for ensifentrine as a maintenance treatment for chronic obstructive pulmonary disease in the leading peer reviewed journal, Respiratory Research.

First Study to Explore a Treat-to-Target Strategy in Crohn’s Disease Using Endoscopy to Guide Dose Adjustment

Ascensia Diabetes Care, a leading global diabetes care company, announced that they will be continuing their support for this years’ Spare a Rose campaign.

OncoDNA, the healthcare technology company making precision medicine a reality, announced that it has completed a €19 million Series B equity financing.

Global Cord Blood Corporation (NYSE: CO) (“GCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today provided an update on the impact of the 2019 novel coronavirus (“2019-nCoV”) on its operations.

Bristol-Myers Squibb Company (NYSE:BMY) today announced the results of a robust multinational inflammatory bowel disease (IBD) survey conducted among patients and physicians, with findings revealing urgent and unmet needs in several key areas, including differences in expectations between patients and physicians that may impact disease management and treatment decisions

Epizyme, Inc. (Nasdaq: EPZM), a fully integrated commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s New Drug Application (NDA) for the accelerated approval of TAZVERIK™ (tazemetostat) for patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior lines of systemic therapy.